MarketAxess to Participate in the Goldman Sachs U.S. Financial Services Conference
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) — MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading […]
Highland Copper Provides an Update on White Pine Closing
LONGUEUIL, Quebec, Dec. 03, 2018 (GLOBE NEWSWIRE) — Highland Copper Company Inc. (TSX-V: HI, OTCQB: HDRSF) (the “Company”) and Copper […]
Templeton Emerging Markets Fund ("EMF") Announces Distribution
FORT LAUDERDALE, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) — Templeton Emerging Markets Fund (NYSE: EMF) today announced a total distribution […]
Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors
– Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate […]
Fortis fait don de 500 000 dollars à la campagne de mobilisation de fonds « Set the Stage »
ST. JOHN’S, Terre-Neuve-et-Labrador, 03 déc. 2018 (GLOBE NEWSWIRE) — Barry Perry, président et PDG de Fortis Inc. (« Fortis » ou la « Société ») a […]
TSX News -
Mega Uranium Ltd. Proposes Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 03, 2018 […]
Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
— Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median […]
Templeton Dragon Fund, Inc. (“TDF”) Announces Distribution
FORT LAUDERDALE, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) — Templeton Dragon Fund, Inc. (NYSE: TDF) today announced a total distribution […]
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple Myeloma ALLO-715 Investigational New Drug Application and Initiation of […]
Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)
– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML […]
